BIOA

BioAge Labs, Inc.
CAPPED RATING

BioAge Labs, Inc. (BIOA) is rated C (2.3/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B); its weakest is Momentum (D-). The rating has held at C for 4 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.3 / 5.0
C
Value
B
Factor Score 3.3 / 5.0
Growth
C
Factor Score 2.2 / 5.0
Profitability
C
Factor Score 2.2 / 5.0
Momentum
D-
Factor Score 1.0 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -2.0
EV / EBITDA 0.3
Rev Growth YoY -85.5%
Gross Margin 0.0%
Price Return 3M -50.1%
Price Return 12M -32.4%
Catalyst Signal 0.00
Market Cap $239.9M
TTM Revenue $8.6M
Price / Sales 27.9
ROE -34.6%

Historical Factor Score Progression

Held C for 4 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-17 B (3.3) C (2.2) C (2.2) D- (1.0) C+ (2.6) C (2.3)
2026-11-10 B (3.3) C- (2.1) C (2.2) D (1.2) C+ (2.6) C (2.3)
2026-11-03 B (3.3) C+ (2.7) C (2.3) D (1.2) C+ (2.7) C (2.4)
2026-10-27 B (3.3) C+ (2.7) C (2.3) D- (1.0) C+ (2.6) C (2.4)
2026-10-20 B (3.3) C+ (2.7) C (2.3) D+ (1.5) C+ (2.6) C (2.5)
Page 1 of 4